Stockscreener 앱 받기
41.23
0.55%
-0.23
시간 외 거래:
41.23
전일 마감가:
$41.46
열려 있는:
$41.33
하루 거래량:
1.05M
Relative Volume:
1.43
시가총액:
$2.31B
수익:
$651.97M
순이익/손실:
$59.71M
주가수익비율:
38.55
EPS:
1.0696
순현금흐름:
$172.03M
1주 성능:
+16.12%
1개월 성능:
+28.48%
6개월 성능:
+7.37%
1년 성능:
+30.97%
1일 변동 폭
$40.26
$41.76
1주일 범위
$35.51
$43.62
52주 변동 폭
$29.16
$43.62
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
Supernus Pharmaceuticals Inc
전화
301-838-2500
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
SUPN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
41.23 | 2.38B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
147.35 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.54 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.37 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.50 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-09-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 재개 | Jefferies | Buy |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-04-13 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 재개 | Jefferies | Hold |
| 2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2019-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-11-12 | 재확인 | B. Riley FBR | Buy |
| 2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-08 | 업그레이드 | Stifel | Hold → Buy |
| 2017-10-19 | 개시 | FBR & Co. | Buy |
| 2017-09-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 개시 | Janney | Neutral |
| 2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2015-11-05 | 재확인 | Northland Capital | Outperform |
| 2015-10-28 | 개시 | Northland Capital | Outperform |
모두보기
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
RSI + MACD Show Convergence for Supernus Pharmaceuticals Inc.High Conviction Intraday Stock Signals Detected - metal.it
CEO’s Major Stock Sale Shakes Up Supernus Pharmaceuticals - TipRanks
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2025 Earnings Call Transcript - Insider Monkey
Supernus Pharmaceuticals Shares Dip Amid Growth Plans - TipRanks
Supernus Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks
SUPN Stock Surge: What’s Driving It? - StocksToTrade
Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today - TradingView
Supernus Pharmaceuticals price target raised to $43 from $38 at Stifel - Investing.com Canada
Supernus Pharmaceuticals (SUPN) Price Target Raised by Cantor Fi - GuruFocus
Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD - Investing.com
Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD By Investing.com - Investing.com Canada
Supernus 2025 Q2 Earnings Mixed Results as Net Income Grows 13% - AInvest
Supernus Pharmaceuticals Q2 CY2025 Financial Results: Exceeding Market ExpectationsNews and Statistics - IndexBox
Supernus: Q2 Earnings Snapshot - New Haven Register
Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... - Yahoo Finance
Supernus Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Supernus Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Supernus Pharmaceuticals Delivers Growth With Qelbree And GOCOVRI - Finimize
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Supernus Pharmaceuticals Q2 2025: Navigating Contradictions in ONAPGO, Qelbree, and ZURZUVAE Growth - AInvest
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales - Yahoo Finance
Earnings call transcript: Supernus Q2 2025 revenue beats forecast, EPS misses By Investing.com - Investing.com South Africa
Supernus Pharmaceuticals Q2 revenue falls - MarketScreener
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SUPERNUS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Supernus Pharmaceuticals Announces Q2 2025 Financial Results and Acquisition of Sage Therapeutics - Quiver Quantitative
Supernus Announces Second Quarter 2025 Financial Results - GlobeNewswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Earnings Report PreviewNews and Statistics - IndexBox
Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
When is Supernus Pharmaceuticals Inc. stock expected to show significant growthExceptional growth trajectory - Jammu Links News
What makes Supernus Pharmaceuticals Inc. stock price move sharplyAchieve superior returns through strategic trading - Jammu Links News
Is Supernus Pharmaceuticals Inc. a growth stock or a value stockFree Investment Timing Strategies - Jammu Links News
What are the technical indicators suggesting about Supernus Pharmaceuticals Inc.Rapid market gains - Jammu Links News
Why is Supernus Pharmaceuticals Inc. stock attracting strong analyst attentionUnlock daily market insights for better trades - Jammu Links News
Should I hold or sell Supernus Pharmaceuticals Inc. stock in 2025Build wealth steadily with proven methods - Jammu Links News
What are analysts’ price targets for Supernus Pharmaceuticals Inc. in the next 12 monthsStay ahead with daily expert stock picks - Jammu Links News
Is Supernus Pharmaceuticals Inc. a good long term investmentSuperior portfolio returns - Jammu Links News
Supernus Acquires Sage Therapeutics to Strengthen Neuropsychiatric Portfolio - AInvest
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics - Yahoo Finance
SAGE Therapeutics Announces Nasdaq Delisting Following Merger and Board Changes - AInvest
What institutional investors are buying Supernus Pharmaceuticals Inc. stockTop Growth Ideas For 2025 - Jammu Links News
Supernus completes acquisition of Sage Therapeutics for $8.50 per share By Investing.com - Investing.com Nigeria
Supernus completes acquisition of Sage Therapeutics for $8.50 per share - Investing.com
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewswire
Supernus Pharmaceuticals Acquires Sage Therapeutics to Strengthen Presence in Neuropsychiatric Conditions - AInvest
Supernus' $200M Sage Therapeutics Acquisition Adds First-Ever Oral Postpartum Depression Drug - Stock Titan
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.43%
0.47%
자본화:
|
볼륨(24시간):